ABSTRACT
Before release onto the market, it must be demonstrated that the total and free polysaccharide (poly ribosyl-ribitol-phosphate, PRP) content of Haemophilus influenzae type b (Hib) vaccine complies with requirements. However, manufacturers use different methods to assay PRP content: a national control laboratory must establish and validate the relevant manufacturer methodology before using it to determine PRP content. An international study was organised by the World Health Organization (WHO), in collaboration with the Biological Standardisation Programme (BSP) of the Council of Europe/European Directorate for the Quality of Medicines & HealthCare (EDQM) and of the European Union Commission, to verify the suitability of a single method for determining PRP content in liquid pentavalent vaccines (DTwP-HepB-Hib) containing a whole-cell pertussis component. It consists of HCl hydrolysis followed by chromatographic separation and quantification of ribitol on a CarboPac MA1 column using high-performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD). The unconjugated, free, PRP is separated from the total PRP using C4 solid-phase extraction cartridges (SPE C4). Ten quality control laboratories performed two independent analyses applying the proposed analytical test protocol to five vaccine samples, including a vaccine lot with sub-potent PRP content and very high free PRP content. Both WHO PRP standard and ribitol reference standard were included as calibrating standards. A significant bias between WHO PRP standard and ribitol reference standard was observed. Study results showed that the proposed analytical method is, in principle, suitable for the intended use provided that a validation is performed as usually expected from quality control laboratories.
Subject(s)
Chromatography, High Pressure Liquid/standards , Chromatography, Ion Exchange/standards , Diphtheria-Tetanus-Pertussis Vaccine/analysis , Haemophilus Vaccines/analysis , Haemophilus influenzae type b/immunology , Hepatitis B Vaccines/analysis , Polysaccharides, Bacterial/analysis , Polysaccharides/analysis , Bacterial Capsules/immunology , Diphtheria-Tetanus-Pertussis Vaccine/immunology , Diphtheria-Tetanus-Pertussis Vaccine/standards , Drug Compounding , Europe , Haemophilus Vaccines/immunology , Haemophilus Vaccines/standards , Hepatitis B Vaccines/immunology , Hepatitis B Vaccines/standards , India , Polysaccharides/immunology , Polysaccharides/standards , Polysaccharides, Bacterial/immunology , Polysaccharides, Bacterial/standards , Quality Control , Reference Standards , Reproducibility of Results , Republic of KoreaABSTRACT
Serological surveys for diphtheria were conducted in six European countries including Czech Republic, Hungary, Ireland, Latvia, Luxembourg, Slovakia and one country outside Europe, Israel. For each country, a nationally representative population sample was collected across the entire age range and was tested for antibodies to diphtheria toxin. Although each national laboratory used its preferred assay, the results were all standardized to those of the in vitro neutralization test and expressed in international units (IU) which allowed comparative analyses to be performed. The results showed that increasing age is related to a gradual increase in seronegative subjects (<0·01 IU/ml of diphtheria antitoxin antibodies). This may reflect waning immunity following childhood vaccination without repeated booster vaccinations in adults. Differences in seronegativity were also found according to gender. In subjects aged 1-19 years, geometric mean titres of antitoxin are clearly related to the different vaccination schedules used in the participating countries. Although clinical disease remains rare, the susceptibility to diphtheria observed in these serosurveys highlights the importance of strengthened surveillance.
Subject(s)
Diphtheria/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Antitoxins/blood , Child , Child, Preschool , Europe/epidemiology , Female , Humans , Infant , Israel/epidemiology , Male , Middle Aged , Neutralization Tests/methods , Neutralization Tests/standards , Seroepidemiologic Studies , Young AdultABSTRACT
Diphtheria is now rare in most European countries but, when cases do arise, the case fatality rate is high (5-10%). Because few countries continue to routinely screen for the causative organisms of diphtheria, the extent to which they are circulating amongst different European populations is largely unknown. During 2007-2008, ten European countries each screened between 968 and 8551 throat swabs from patients with upper respiratory tract infections. Six toxigenic strains of Corynebacterium diphtheriae were identified: two from symptomatic patients in Latvia (the country with the highest reported incidence of diphtheria in the European Union) and four from Lithuania (two cases, two carriers); the last reported case of diphtheria in Lithuania was in 2002. Carriage rates of non-toxigenic organisms ranged from 0 (Bulgaria, Finland, Greece, Ireland, Italy) to 4.0 per 1000 (95% CI 2.0-7.1) in Turkey. A total of 28 non-toxigenic strains were identified during the study (26 C. diphtheriae, one Corynebacterium ulcerans, one Corynebacterium pseudotuberculosis). The non-toxigenic C. ulcerans strain was isolated from the UK, the country with the highest reported incidence of cases due to C. ulcerans. Of the eleven ribotypes detected, Cluj was seen most frequently in the non-toxigenic isolates and, amongst toxigenic isolates, the major epidemic clone, Sankt-Petersburg, is still in circulation. Isolation of toxigenic C. diphtheriae and non-toxigenic C. diphtheriae and C. ulcerans in highly-vaccinated populations highlights the need to maintain microbiological surveillance, laboratory expertise and an awareness of these organisms amongst public health specialists, microbiologists and clinicians.
Subject(s)
Corynebacterium Infections/diagnosis , Corynebacterium Infections/epidemiology , Corynebacterium/isolation & purification , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/microbiology , Adolescent , Adult , Aged , Carrier State/epidemiology , Carrier State/microbiology , Child , Child, Preschool , Corynebacterium Infections/microbiology , Corynebacterium diphtheriae/isolation & purification , Corynebacterium pseudotuberculosis/isolation & purification , Europe/epidemiology , Humans , Incidence , Infant , Mass Screening , Middle Aged , Pharynx/microbiology , Young AdultABSTRACT
The European Pharmacopoeia (Ph. Eur.) and the World Health Organization (WHO) require the performance of extensive quality control testing including a potency test before a vaccine batch is released for human use. Whole cell pertussis (wP) vaccine potency is assessed by a mouse protection test (MPT) based on the Kendrick test. This test compares the vaccine dose necessary to protect 50% of mice against the effect of a lethal intracerebral dose of Bordetella pertussis and the dose of a suitable reference vaccine needed to give the same protection level. Due to the large variability in the results of this test and the severe distress which is inflicted on the many animals involved, its replacement by an alternative method is highly desirable. At the initiative of the European Directorate for the Quality of Medicines and HealthCare (EDQM) of the Council of Europe, in collaboration with the WHO and the In-vitro toxicology Unit/European Centre for the Validation of Alternative Methods (ECVAM) of the European Commission (EC) Joint Research Centre-Institute for Health and Consumer Protection (JRC-IHCP), wP vaccine specialists from all over the world were invited to present an overview of candidate alternatives at a symposium organised in Geneva (Switzerland) in March 2005. Although no alternative method was found suitable for immediate implementation of batch potency control, the Pertussis Serological Potency Test (PSPT), initially developed in mice and recently transferred to guinea pigs (gps), was identified as a model of interest. Using the PSPT in gps to test several components of combined vaccines such as Diphtheria-Tetanus-wP vaccines in the same animal series would allow further implementation of the European 3Rs policy to batch potency control, by additional method refinement and reduction of animal use. The present study evaluated 2 features of the serological response to wP vaccination: 1) the overall antibody response as measured by a "whole cell" ELISA (PSPT-wC-ELISA) which uses the B. pertussis 18323 challenge strain prescribed for the MPT to coat the assay plates and 2) the functional neutralising antibodies to pertussis toxin (PT, one of the main virulence factors of B. pertussis), as measured by the Chinese Hamster Ovary (CHO) cell assay. The results showed that 1) the gp model can be used for wP vaccine potency testing; 2) despite good repeatability and precision, the CHO cell assay did not generate results comparable to the MPT. Moreover, the CHO cell assay showed significant differences in the ability of wP vaccines to induce neutralising anti-PT antibodies, which did not correlate to the overall antibody response evaluated by PSPT-wC-ELISA; 3) comparable potencies were obtained in the MPT and the PSPT-wC-ELISA. This study, supported by the previous ones correlating the PSPT-wC-ELISA in mice with the MPT, confirms that PSPT-wC-ELISA in gps is a promising approach for batch release potency testing of wP vaccines for which consistency in production has already been demonstrated by the MPT. However, a large scale validation study is required prior to the adoption of PSPT-wC-ELISA as a compendial reference method for wP vaccines batch release control.
Subject(s)
Immunity, Cellular/immunology , Pertussis Vaccine/immunology , Serologic Tests/methods , Animals , CHO Cells , Cricetinae , Cricetulus , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay/standards , Europe , Female , Guinea Pigs , Male , Mice , Pertussis Vaccine/standardsABSTRACT
BACKGROUND & OBJECTIVES: Type-specific antibodies against M protein are critical for human protection as they enhance phagocytosis and are protective. An ideal vaccine for the protection against Streptococcus pyogenes would warrant mucosal immunity, but mucosally administered M-protein has been shown to be poorly immunogenic in animals. We used a recombinant M type 6 protein to immunize mice in the presence of synthetic oligodeoxynucleotides containing CpG motifs (immunostimulatory sequences: ISS) or cholera toxin (CT) to explore its possible usage in a mucosal vaccine. METHODS: Mice were immunized by intranasal (in) or intradermal (id) administration with four doses at weekly intervals of M6-protein (10 microg/mouse) with or without adjuvant (ISS, 10 microg/mouse or CT, 0,5 microg/mouse). M6 specific antibodies were measured by enzyme linked immunosorbent assay using class and subclass specific monoclonal antibodies. RESULTS: The use of ISS induced an impressive anti M-protein serum IgG response but when id administered was not detectable in the absence of adjuvant. When used in, M-protein in the presence of both ISS and CT induced anti M-protein IgA in the bronchoalveolar lavage, as well as specific IgG in the serum. IgG were able to react with serotype M6 strains of S. pyogenes. The level of antibodies obtained by immunizing mice in with M-protein and CT was higher in comparison to M-protein and ISS. The analysis of anti-M protein specific IgG subclasses showed high levels of IgG1, IgG2a and IgG2b, and low levels of IgG3 when ISS were used as adjuvant. Thus, in the presence of ISS, the ratio IgG2a/IgG1 and (IgG2a+IgG3)/IgG1 >1 indicated a type 1-like response obtained both in mucosally or systemically vaccinated mice. INTERPRETATION & CONCLUSION: Our study offers a reproducible model of anti-M protein vaccination that could be applied to test new antigenic formulations to induce an anti-group A Streptococcus (GAS) vaccination suitable for protection against the different diseases caused by this bacterium.
Subject(s)
Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Carrier Proteins/immunology , CpG Islands , Oligodeoxyribonucleotides/immunology , Animals , Antigens, Bacterial/administration & dosage , Bacterial Outer Membrane Proteins/administration & dosage , Base Sequence , Carrier Proteins/administration & dosage , DNA Primers , Enzyme-Linked Immunosorbent Assay , Mice , Oligodeoxyribonucleotides/administration & dosage , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunologyABSTRACT
Twenty-four strains of non-toxigenic Corynebacterium diphtheriae biotype gravis from the throats of patients with pharyngitis/tonsillitis were assayed for susceptibility to penicillin and erythromycin using determination of MIC, MBC and time-kill curves. There were no differences between the MICs of penicillin for susceptible and tolerant strains. All but one strain had penicillin MBCs > or = 2 mg/L. Seventy-one per cent (17/24) of the strains were tolerant to penicillin. In contrast, all strains were susceptible to erythromycin (MIC < or = 0.016 mg/L). These aspects should be considered when choosing the therapy for treating non-toxigenic C. diphtheriae pharyngitis/tonsillitis.
Subject(s)
Anti-Bacterial Agents/pharmacology , Corynebacterium diphtheriae/drug effects , Penicillin Resistance , Penicillins/pharmacology , Pharyngitis/microbiology , Anti-Bacterial Agents/therapeutic use , Corynebacterium diphtheriae/isolation & purification , Erythromycin/pharmacology , Erythromycin/therapeutic use , Humans , Microbial Sensitivity Tests , Penicillins/therapeutic use , Pharyngitis/drug therapy , Treatment OutcomeABSTRACT
We evaluated the reactogenicity and immunogenicity of a booster dose of diphtheria-tetanus vaccine administered at the age of school-entry, comparing a low-dose vaccine (dT) to the standard paediatric dose (DT). Participants were randomly assigned to receive one of the two vaccines; the study was evaluator-blinded. The frequency of side-reactions was similar when comparing the two groups, except when considering local redness and swelling, which were significantly more frequent among the DT group. The post-booster geometric mean titre of diphtheria antibodies in the DT group was twice as high as that in the dT group (14.1 IU/ml versus 7.7 IU/ml; P<0.001). The higher antibody response and the comparable reactogenicity indicate that DT should be used as booster at school-entry, particularly if additional booster doses during adolescence or adulthood are not administered.
Subject(s)
Diphtheria-Tetanus Vaccine/administration & dosage , Immunization, Secondary , Antibodies, Bacterial/biosynthesis , Antibodies, Bacterial/immunology , Child , Clostridium tetani/immunology , Corynebacterium diphtheriae/immunology , Diphtheria-Tetanus Vaccine/adverse effects , Diphtheria-Tetanus Vaccine/immunology , Enzyme-Linked Immunosorbent Assay , Female , Fever/chemically induced , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/immunology , Male , Prospective Studies , Safety , Single-Blind MethodABSTRACT
Synthetic oligodeoxynucleotides containing CpG immunostimulatory sequences (ISS) have been shown to act as potent adjuvants of type 1 immune responses when co-administered with protein or peptide vaccines. We have recently shown that ISS can increase the anti-polysaccharide (CHO) and anti-tetanus toxoid (TT) or anti-diphtheria (CRM) toxoid antibody levels if used as adjuvant of anti-Haemophilus influenzae type b (Hib) CHO vaccine conjugated with TT or CRM. The analysis of anti-TT and anti-CRM IgG subclasses showed a significant increase in IgG2a, IgG2b and/or IgG3 in the presence of ISS. Anti-TT and anti-CRM antibodies were shown to neutralize the activity of both the tetanus and diphtheria toxin in vivo or in vitro tests respectively. These data show that ISS have the potential to increase host antibody response against both the CHO and the protein component of a conjugated vaccine, and encourage the investigation to identify strategies of vaccination with schedules aimed at the valuation of protein carriers as protective immunogens.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Haemophilus Vaccines/administration & dosage , Haemophilus influenzae/immunology , Oligodeoxyribonucleotides/administration & dosage , Animals , Antibodies, Bacterial/biosynthesis , Bacterial Capsules , Base Sequence , CpG Islands , Diphtheria Toxoid/administration & dosage , Female , Glycoconjugates/administration & dosage , Glycoconjugates/immunology , Haemophilus Vaccines/immunology , Immunoglobulin G/biosynthesis , Immunoglobulin G/classification , Mice , Mice, Inbred BALB C , Neutralization Tests , Oligodeoxyribonucleotides/genetics , Polysaccharides, Bacterial/immunology , Tetanus Toxoid/administration & dosageABSTRACT
The susceptibilities of C3H/HeN, BALB/c, and C57BL/6N mouse strains to group B streptococci (GBS) infection were evaluated. C3H/HeN mice developed severe polyarthitis; mild lesions and no lesions were observed in BALB/c and C57BL/6N mice, respectively. A correlation between the severity of arthritis, the number of GBS in the joints, and local interleukin-6 and interleukin-1beta production was evident.
Subject(s)
Arthritis, Infectious/immunology , Streptococcal Infections/immunology , Streptococcus agalactiae , Animals , Disease Susceptibility , Interleukin-1/biosynthesis , Interleukin-6/biosynthesis , Mice , Mice, Inbred Strains , Species SpecificityABSTRACT
Seven countries in Western Europe collected large, representative serum banks across the entire age range and tested them for diphtheria anti-toxin (sample size ranged from 2991 to 7715). Although a variety of assays were used, the results were all standardized to those of a reference laboratory and expressed in international units. The standardization process, and the availability of similar, large data sets allowed comparative analyses to be performed in which a high degree of confidence could be ascribed to observed epidemiological differences. The results showed that there were large differences in the proportion of adults with insufficient levels of protection amongst different countries. For instance, roughly 35% of 50- to 60-year-olds were found to be seronegative (titre < or = 0.01 IU/ml) in Finland compared with 70-75% in the United Kingdom. Furthermore, the proportion of seronegative adults would be expected to increase in some countries, notably Italy and the western part of Germany. In those countries with vaccination of military recruits there was a marked sex-related difference in the proportion of seropositive individuals. All countries have high levels of infant vaccine coverage (> 90%) but the accelerated schedule in the United Kingdom appears to result in lower anti-toxin titres than elsewhere. In Sweden, booster doses are not offered until 10 years of age which results in large numbers of children with inadequate levels of protection. Although the United Kingdom and Sweden both have higher proportions of seronegative children than elsewhere the likelihood of a resurgence of diphtheria in these countries seems remote.
Subject(s)
Diphtheria Antitoxin/blood , Diphtheria Toxoid , Diphtheria/epidemiology , Immunization Schedule , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Diphtheria/blood , Diphtheria/immunology , Diphtheria/prevention & control , Diphtheria Antitoxin/immunology , Enzyme-Linked Immunosorbent Assay , Europe/epidemiology , Female , Humans , Infant , Male , Middle Aged , Seroepidemiologic Studies , Sex FactorsABSTRACT
Immunity to diphtheria was assessed in serum samples obtained from 3111 healthy Italian males and females aged 0-84 years. Diphtheria antitoxin was tested using a double-antigen, time-resolved fluorescence immunoassay (DA-DELFIA). According to internationally accepted criteria, antitoxin concentrations < 0.01 IU/ml indicate susceptibility to diphtheria, those > or = 0.01-0.09 IU/ml provide basic or inadequate protection, and concentrations > or =0.1 IU/ml are protective. By these criteria, 9.9% (95% CI 8.9 to 11.18) of the participants were susceptible to diphtheria, 30.2% (95% CI, 28.6 to 31.9) had basic protection, and 59.9% (95% CI, 58.1 to 61.6) were protected. The prevalence of unprotected individuals showed an age-related increase, up to the 45-49-year-old age group for females and the 50-54-year-old age group for males (34.9% and 31.3% of individuals, respectively). The prevalence of immunity did not significantly differ in relation to sex in any of the age groups. These results indicate that booster shots should be routinely provided to the adult population in order to maintain a protective level of diphtheria antibodies.
Subject(s)
Diphtheria Antitoxin/blood , Diphtheria/immunology , Adolescent , Adult , Age Factors , Child , Child, Preschool , Diphtheria Toxoid , Disease Susceptibility , Female , Fluorescent Antibody Technique , Humans , Immunization, Secondary , Infant , Italy , Male , Middle Aged , Sex FactorsABSTRACT
Septic arthritis is a clinical manifestation of group B streptococcal (GBS) infection in neonates and adults. To examine the potential role of GBS beta-hemolysin in joint injury, mice were infected with 2 wild-type strains or with nonhemolytic (NH) or hyperhemolytic (HH) variants derived by transposon mutagenesis. Compared with mice infected with the parent strains, mice infected with the NH mutants had decreased mortality and bacterial proliferation. A reduced LD(50) and a higher microbial load were obtained in mice infected with the HH mutants. Greater degrees of joint inflammation and damage were observed in the HH mutant-infected animals than in those infected with the parental strains. NH mutant-infected mice manifested only a mild and transient arthritis. Systemic and local levels of interleukin-6 mirrored the observed differences in virulence and severity of arthritis. These data support a direct correlation of GBS beta-hemolysin expression with mortality and severity of articular lesions.
Subject(s)
Arthritis, Infectious/metabolism , Hemolysin Proteins/biosynthesis , Streptococcal Infections/metabolism , Animals , Disease Models, Animal , Female , Inflammation/microbiology , Interleukin-6/metabolism , Lethal Dose 50 , Male , Mice , Streptococcus/genetics , Streptococcus/metabolism , Streptococcus/pathogenicityABSTRACT
A European Sero-Epidemiological Network (ESEN) was established with the aim to co-ordinate and harmonise serological surveillance of immunity to communicable diseases in Europe. In this study the inter-laboratory standardisation of diphtheria toxin antibody measurements is reported. A standard panel of 162 sera was tested by the participating laboratories using an in vitro assay of their choice: VERO cell toxin neutralisation assay (NT), double-antigen delayed time-resolved fluorescence immuno-assay (DA-DELFIA), double-antigen enzyme-linked immunosorbent assay (DAE), toxin binding inhibition test (ToBI) and an indirect enzyme-linked immunosorbent assay (ELISA). The results were standardised using regression against the NT. The variations due to inter-laboratory and inter-assay variation, which would otherwise make it difficult directly to compare the main serum bank results by the different laboratories and the various assays were successfully minimised by the standardisation. The regression equations obtained will be used to transform the respective local results of testing the main serum bank into the reference test unitages. This study also gave the opportunity to compare the various assays within and between laboratories. This demonstrated a very high correlation between DA-DELFIA, DAE, ToBI and the NT. The ELISA showed a good correlation, too, however sera below some 0.1 IU/ml were overestimated.
Subject(s)
Diphtheria Antitoxin/analysis , Animals , Chlorocebus aethiops , Enzyme-Linked Immunosorbent Assay/standards , Humans , Immunoassay/standards , Neutralization Tests , Regression Analysis , Vero CellsABSTRACT
Synthetic oligodeoxynucleotides containing CpG motifs [immunostimulatory sequences (ISS)] have been described as potent adjuvants of type 1 immune responses when co-administered with protein or peptide vaccines. To investigate their role in the immune response to polysaccharides (CHO), different preparations of anti-Haemophilus influenzae type b (Hib) conjugate vaccine were administered to mice. The unconjugated CHO did not induce the synthesis of specific antibodies even in the presence of ISS. On the other hand, anti-CHO-specific antibodies significantly increased in the presence of ISS, when tetanus (TT) or diphtheria [cross-reacting material (CRM)] toxoid-conjugated CHO were used to immunize mice. The adjuvant effect was also observed for the immune response against the carrier protein (TT and CRM). ISS insured an early and long-lasting specific IgG production. The effects of ISS on the anti-CHO immune response could be attributed to the amplification of the T help provided by the carrier. The analysis of anti-CHO IgG subclasses showed a significant increase of IgG2a and IgG3 in the presence of ISS. ISS caused a rapid release of IL-12 and IFN-gamma in sera from treated mice. This data provide a first evidence for the ability of ISS to induce an anti-CHO type 1-like immune response and demonstrate that ISS have the potential to increase host antibody response against both the CHO and the protein component of a conjugated vaccine.
Subject(s)
Adjuvants, Immunologic/pharmacology , Antibodies, Bacterial/biosynthesis , CpG Islands , Haemophilus Vaccines/immunology , Immunoglobulin G/biosynthesis , Oligodeoxyribonucleotides/immunology , Polysaccharides, Bacterial/immunology , Th1 Cells/immunology , Animals , Bacterial Capsules , Cytokines/metabolism , Diphtheria Toxoid/immunology , Drug Carriers , Female , Immunization , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Tetanus Toxoid/immunologyABSTRACT
Several group B streptococcal products have been previously found to stimulate human monocytes to produce tumor necrosis factor alpha. In order to identify the receptors involved in these responses, monocytes were stimulated with purified group- or type-specific carbohydrates or lipoteichoic acid in the presence of anti-receptor monoclonal antibodies, soluble CD14, or lipopolysaccharide-binding protein. Results indicate that CD14 plays an important role in tumor necrosis factor alpha responses to all of the stimuli tested. Moreover, both CD14 and complement receptor type 3 may be involved in responses to the group-antigen.
Subject(s)
Lipopolysaccharide Receptors/physiology , Monocytes/physiology , Receptors, Tumor Necrosis Factor/physiology , Streptococcus agalactiae/physiology , Tumor Necrosis Factor-alpha/biosynthesis , Animals , Humans , Lipopolysaccharides/pharmacology , Macrophage-1 Antigen/physiology , Mice , Polysaccharides, Bacterial/pharmacology , Teichoic Acids/pharmacologyABSTRACT
OBJECTIVE: To assess the effect of interferon-gamma (IFNgamma) administration on the evolution of systemic infection and septic arthritis induced by group B streptococci (GBS) in mice. METHODS: CD1 mice were inoculated intravenously with arthritogenic strain 1/82 of type IV GBS. Exogenous murine IFNgamma or anti-IFNgamma monoclonal antibodies were administered intravenously either 2 hours (-2 hours) before or 18 hours after infection with 1 x 10(7) GBS. Mice were monitored daily for survival and for signs of arthritis. In a subsequent set of experiments, mice were killed at selected times for examination of bacterial clearance, joint histopathology, and cytokine production. RESULTS: Mortality in mice treated with IFNgamma at -2 hours was 100%, compared with 20% in those treated at 18 hours and with 40% in controls. As indicated by the arthritis score, mice treated with IFNgamma at -2 hours developed early and more severe arthritis, whereas those treated at 18 hours had milder arthritis compared with infected controls. Less severe joint pathology in the mice treated with IFNgamma at 18 hours correlated with low levels of interleukin-6 (IL-6) and IL-1beta and a low bacterial load in the joints, whereas rapid onset and worsening of articular lesions in those treated at -2 hours corresponded to early and sustained levels of IL-6. CONCLUSION: The findings of this study demonstrate that the effects mediated by IFNgamma on GBS-induced arthritis may be detrimental or beneficial, depending on the time of administration of IFNgamma in relation to infection with the antigen.
Subject(s)
Arthritis, Infectious/physiopathology , Cartilage, Articular , Interferon-gamma/administration & dosage , Interferon-gamma/physiology , Streptococcal Infections , Streptococcus agalactiae , Animals , Antigens, Bacterial/administration & dosage , Arthritis, Infectious/mortality , Cartilage, Articular/immunology , Cartilage, Articular/microbiology , Female , Joints/pathology , Male , Mice , Severity of Illness Index , Streptococcal Infections/physiopathology , Streptococcus agalactiae/immunologyABSTRACT
Intravenous inoculation of CD1 mice with 10(7) CFU of type IV group B Streptococcus (GBS IV) results in a high incidence of diffuse septic arthritis. In this study the roles of tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6 in articular pathology were evaluated. Cytokine levels were quantified in the serum and joints by enzyme-linked immunosorbent assay in mice injected with GBS IV and tested or not tested with pentoxifylline (PTF), a methylxanthine that affects cytokine production. PTF was administered intraperitoneally at a dose of 1 mg/mouse (50 mg/kg of body weight) 1 h after GBS infection and then at 24-h intervals for 4 days. High levels of IL-1beta and IL-6, but not TNF-alpha, were detected in the joints of mice injected with GBS IV from 5 to 15 days after infection, when articular lesions were most frequent and severe. IL-1beta and IL-6 concentrations in the joints significantly (P < 0.001) exceeded those detected in the serum, confirming a strong local production. PTF treatment resulted in a strong reduction of cytokine production and in a marked decrease in both the incidence and severity of arthritis. Inoculation of exogenous murine recombinant IL-1beta or IL-6 in mice treated with GBS IV plus PTF resulted in an incidence and severity of articular lesions similar to those obtained with inoculation of GBS IV alone. No significant effect was obtained with TNF-alpha administration. These data show a strong involvement of IL-1beta and IL-6, but not TNF-alpha, in the pathogenesis of GBS arthritis.
Subject(s)
Arthritis, Infectious/immunology , Interleukin-1/immunology , Interleukin-6/immunology , Streptococcal Infections/immunology , Streptococcus agalactiae/immunology , Tumor Necrosis Factor-alpha/immunology , Animals , Arthritis, Infectious/epidemiology , Arthritis, Infectious/physiopathology , Female , Incidence , Interleukin-1/administration & dosage , Interleukin-1/antagonists & inhibitors , Interleukin-1/biosynthesis , Interleukin-6/administration & dosage , Interleukin-6/antagonists & inhibitors , Interleukin-6/biosynthesis , Kinetics , Male , Mice , Pentoxifylline/administration & dosage , Pentoxifylline/pharmacology , Streptococcal Infections/epidemiology , Streptococcal Infections/physiopathology , Streptococcus agalactiae/growth & development , Streptococcus agalactiae/pathogenicity , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
The molecular size of Haemophilus influenzae (Hib) type b polysaccharide-protein conjugate vaccines is an important physico-chemical parameter which correlates with immunogenicity. This paper describes the experimental conditions for high-performance size-exclusion chromatography on a PL Aquagel-OH 60 column to determine the size distribution of Hib high-molecular-weight conjugate vaccines.
Subject(s)
Bacterial Vaccines/chemistry , Chromatography, Gel/methods , Haemophilus influenzae/immunology , Tetanus Toxoid/immunology , Vaccines, Synthetic/chemistry , Molecular WeightABSTRACT
High-performance size exclusion chromatography has been used to determine the molecular size distribution of Haemophilus influenzae type b (Hib) conjugate vaccines. Both high molecular weight preparations of native Hib capsular polysaccharide coupled to tetanus toxoid and low molecular weight vaccines with Hib oligosaccharides linked to the CRM197 nontoxic mutant diphtheria protein were analysed. Columns with different fractionation ranges were used for the two kinds of vaccines. This method showed to be rapid, accurate and reproducible for different lots of Hib vaccine of different composition produced by various manufacturers. It could replace more time-consuming chromatographic methods enabling control authorities to employ a single methodological approach for different Hib vaccines.